Adolescent peer struggles predict accelerated epigenetic aging in midlife / Joseph P. ALLEN in Development and Psychopathology, 35-2 (May 2023)  

Public ISBD [article]  inDevelopment and Psychopathology > 35-2 (May 2023) . - p.912-925 Titre : Adolescent peer struggles predict accelerated epigenetic aging in midlife Type de document : texte imprimé Auteurs : Joseph P. ALLEN, Auteur ; Joshua S. DANOFF, Auteur ; Meghan A. COSTELLO, Auteur ; Emily L. LOEB, Auteur ; Alida A. DAVIS, Auteur ; Gabrielle L. HUNT, Auteur ; Simon G. GREGORY, Auteur ; Stephanie N. GIAMBERARDINO, Auteur ; Jessica J. CONNELLY, Auteur Article en page(s) : p.912-925 Langues : Anglais (eng) Mots-clés : adolescent  autonomy  epigenetic aging  friendships  longitudinal  peer  social relationships Index. décimale : PER Périodiques Résumé : This study examined struggles to establish autonomy and relatedness with peers in adolescence and early adulthood as predictors of advanced epigenetic aging assessed at age 30. Participants (N = 154; 67 male and 87 female) were observed repeatedly, along with close friends and romantic partners, from ages 13 through 29. Observed difficulty establishing close friendships characterized by mutual autonomy and relatedness from ages 13 to 18, an interview-assessed attachment state of mind lacking autonomy and valuing of attachment at 24, and self-reported difficulties in social integration across adolescence and adulthood were all linked to greater epigenetic age at 30, after accounting for chronological age, gender, race, and income. Analyses assessing the unique and combined effects of these factors, along with lifetime history of cigarette smoking, indicated that each of these factors, except for adult social integration, contributed uniquely to explaining epigenetic age acceleration. Results are interpreted as evidence that the adolescent preoccupation with peer relationships may be highly functional given the relevance of such relationships to long-term physical outcomes. En ligne : http://dx.doi.org/10.1017/S0954579422000153 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=504 [article] Adolescent peer struggles predict accelerated epigenetic aging in midlife [texte imprimé] / Joseph P. ALLEN, Auteur ; Joshua S. DANOFF, Auteur ; Meghan A. COSTELLO, Auteur ; Emily L. LOEB, Auteur ; Alida A. DAVIS, Auteur ; Gabrielle L. HUNT, Auteur ; Simon G. GREGORY, Auteur ; Stephanie N. GIAMBERARDINO, Auteur ; Jessica J. CONNELLY, Auteur . - p.912-925. Langues : Anglais (eng) in Development and Psychopathology > 35-2 (May 2023) . - p.912-925 Mots-clés : adolescent  autonomy  epigenetic aging  friendships  longitudinal  peer  social relationships Index. décimale : PER Périodiques Résumé : This study examined struggles to establish autonomy and relatedness with peers in adolescence and early adulthood as predictors of advanced epigenetic aging assessed at age 30. Participants (N = 154; 67 male and 87 female) were observed repeatedly, along with close friends and romantic partners, from ages 13 through 29. Observed difficulty establishing close friendships characterized by mutual autonomy and relatedness from ages 13 to 18, an interview-assessed attachment state of mind lacking autonomy and valuing of attachment at 24, and self-reported difficulties in social integration across adolescence and adulthood were all linked to greater epigenetic age at 30, after accounting for chronological age, gender, race, and income. Analyses assessing the unique and combined effects of these factors, along with lifetime history of cigarette smoking, indicated that each of these factors, except for adult social integration, contributed uniquely to explaining epigenetic age acceleration. Results are interpreted as evidence that the adolescent preoccupation with peer relationships may be highly functional given the relevance of such relationships to long-term physical outcomes. En ligne : http://dx.doi.org/10.1017/S0954579422000153 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=504

Evaluating placebo responses to intranasal oxytocin in autism: findings from the placebo lead-in phase of a randomised controlled trial / Kelsie A. BOULTON in Journal of Child Psychology and Psychiatry, 67-7 (July 2026)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 67-7 (July 2026) . - p.1085-1094 Titre : Evaluating placebo responses to intranasal oxytocin in autism: findings from the placebo lead-in phase of a randomised controlled trial Type de document : texte imprimé Auteurs : Kelsie A. BOULTON, Auteur ; Rinku THAPA, Auteur ; Yun Ju SONG, Auteur ; Andrew J. O. WHITEHOUSE, Auteur ; Marilena M. DEMAYO, Auteur ; Simon G. GREGORY, Auteur ; Izabella POKORSKI, Auteur ; Joanna GRANICH, Auteur ; Zahava AMBARCHI, Auteur ; John WRAY, Auteur ; Emma E. THOMAS, Auteur ; Ian B. HICKIE, Auteur ; Adam J. GUASTELLA, Auteur Article en page(s) : p.1085-1094 Langues : Anglais (eng) Mots-clés : Treatment  oxytocin  autism  social interaction  anxiety Index. décimale : PER Périodiques Résumé : Background The placebo effect is established in clinical trials, but for paediatric research, questions remain about how to best manage its influence. Within the autism field, data on these issues is sparse. This is particularly important in the oxytocin field where placebo responses are thought to play an important role. This study reports on data from the single-blind, placebo lead-in phase of a randomised controlled trial (RCT) to investigate the placebo response and its relationship to treatment response in autistic children. Methods Eighty-seven autistic children aged 3?12?years (M?=?7.27; SD?=?2.69; 85.1% male) were consecutively recruited into a multi-site RCT evaluating the efficacy of oxytocin for improving social responsiveness. Participants underwent a 3-week, single-blind placebo lead-in before randomisation into a 12-week double-blind treatment phase (oxytocin, n?=?45; placebo, n?=?42). The Social Responsiveness Scale, 2nd Edition (SRS-2) Total Raw Score was used to measure change from baseline to post-placebo lead-in. A ≥10-point improvement defined placebo responders. Results Nearly half the sample (n?=?42, 48.3%) were identified as placebo responders during the lead-in phase, showing a clinically significant degree of change on the SRS-2. Caregiver treatment guess did not significantly impact the placebo response (p?=?.534). Placebo response was associated with greater symptom severity (r's?>??.23; p-values? En ligne : https://doi.org/10.1111/jcpp.70116 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=588 [article] Evaluating placebo responses to intranasal oxytocin in autism: findings from the placebo lead-in phase of a randomised controlled trial [texte imprimé] / Kelsie A. BOULTON, Auteur ; Rinku THAPA, Auteur ; Yun Ju SONG, Auteur ; Andrew J. O. WHITEHOUSE, Auteur ; Marilena M. DEMAYO, Auteur ; Simon G. GREGORY, Auteur ; Izabella POKORSKI, Auteur ; Joanna GRANICH, Auteur ; Zahava AMBARCHI, Auteur ; John WRAY, Auteur ; Emma E. THOMAS, Auteur ; Ian B. HICKIE, Auteur ; Adam J. GUASTELLA, Auteur . - p.1085-1094. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 67-7 (July 2026) . - p.1085-1094 Mots-clés : Treatment  oxytocin  autism  social interaction  anxiety Index. décimale : PER Périodiques Résumé : Background The placebo effect is established in clinical trials, but for paediatric research, questions remain about how to best manage its influence. Within the autism field, data on these issues is sparse. This is particularly important in the oxytocin field where placebo responses are thought to play an important role. This study reports on data from the single-blind, placebo lead-in phase of a randomised controlled trial (RCT) to investigate the placebo response and its relationship to treatment response in autistic children. Methods Eighty-seven autistic children aged 3?12?years (M?=?7.27; SD?=?2.69; 85.1% male) were consecutively recruited into a multi-site RCT evaluating the efficacy of oxytocin for improving social responsiveness. Participants underwent a 3-week, single-blind placebo lead-in before randomisation into a 12-week double-blind treatment phase (oxytocin, n?=?45; placebo, n?=?42). The Social Responsiveness Scale, 2nd Edition (SRS-2) Total Raw Score was used to measure change from baseline to post-placebo lead-in. A ≥10-point improvement defined placebo responders. Results Nearly half the sample (n?=?42, 48.3%) were identified as placebo responders during the lead-in phase, showing a clinically significant degree of change on the SRS-2. Caregiver treatment guess did not significantly impact the placebo response (p?=?.534). Placebo response was associated with greater symptom severity (r's?>??.23; p-values? En ligne : https://doi.org/10.1111/jcpp.70116 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=588

Genetic and epigenetic signatures associated with plasma oxytocin levels in children and adolescents with autism spectrum disorder / Stephen K. SIECINSKI in Autism Research, 16-3 (March 2023)  

Public ISBD [article]  inAutism Research > 16-3 (March 2023) . - p.502-523 Titre : Genetic and epigenetic signatures associated with plasma oxytocin levels in children and adolescents with autism spectrum disorder Type de document : texte imprimé Auteurs : Stephen K. SIECINSKI, Auteur ; Stephanie N. GIAMBERARDINO, Auteur ; Marina SPANOS, Auteur ; Annalise C. HAUSER, Auteur ; Jason R. GIBSON, Auteur ; Tara CHANDRASEKHAR, Auteur ; Maria Del Pilar TRELLES, Auteur ; Carol M. ROCKHILL, Auteur ; Michelle L. PALUMBO, Auteur ; Allyson Witters CUNDIFF, Auteur ; Alicia MONTGOMERY, Auteur ; Paige SIPER, Auteur ; Mendy B. MINJAREZ, Auteur ; Lisa A. NOWINSKI, Auteur ; Sarah MARLER, Auteur ; Lydia C. KWEE, Auteur ; Lauren C. SHUFFREY, Auteur ; Cheryl ALDERMAN, Auteur ; Jordana WEISSMAN, Auteur ; Brooke ZAPPONE, Auteur ; Jennifer E. MULLETT, Auteur ; Hope CROSSON, Auteur ; Natalie HONG, Auteur ; Sheng LUO, Auteur ; Lilin SHE, Auteur ; Manjushri BHAPKAR, Auteur ; Russell DEAN, Auteur ; Abby SCHEER, Auteur ; Jacqueline L. JOHNSON, Auteur ; Bryan H. KING, Auteur ; Christopher J. MCDOUGLE, Auteur ; Kevin B. SANDERS, Auteur ; Soo-Jeong KIM, Auteur ; Alexander KOLEVZON, Auteur ; Jeremy VEENSTRA-VANDERWEELE, Auteur ; Elizabeth R. HAUSER, Auteur ; Linmarie SIKICH, Auteur ; Simon G. GREGORY, Auteur Article en page(s) : p.502-523 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Abstract Oxytocin (OT), the brain's most abundant neuropeptide, plays an important role in social salience and motivation. Clinical trials of the efficacy of OT in autism spectrum disorder (ASD) have reported mixed results due in part to ASD's complex etiology. We investigated whether genetic and epigenetic variation contribute to variable endogenous OT levels that modulate sensitivity to OT therapy. To carry out this analysis, we integrated genome-wide profiles of DNA-methylation, transcriptional activity, and genetic variation with plasma OT levels in 290 participants with ASD enrolled in a randomized controlled trial of OT. Our analysis identified genetic variants with novel association with plasma OT, several of which reside in known ASD risk genes. We also show subtle but statistically significant association of plasma OT levels with peripheral transcriptional activity and DNA-methylation profiles across several annotated gene sets. These findings broaden our understanding of the effects of the peripheral oxytocin system and provide novel genetic candidates for future studies to decode the complex etiology of ASD and its interaction with OT signaling and OT-based interventions. Lay Summary Oxytocin (OT) is an abundant chemical produced by neurons that plays an important role in social interaction and motivation. We investigated whether genetic and epigenetic factors contribute to variable OT levels in the blood. To this, we integrated genetic, gene expression, and non-DNA regulated (epigenetic) signatures with blood OT levels in 290 participants with autism enrolled in an OT clinical trial. We identified genetic association with plasma OT, several of which reside in known autism risk genes. We also show statistically significant association of plasma OT levels with gene expression and epigenetic across several gene pathways. These findings broaden our understanding of the factors that influence OT levels in the blood for future studies to decode the complex presentation of autism and its interaction with OT and OT-based treatment. En ligne : https://doi.org/10.1002/aur.2884 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=498 [article] Genetic and epigenetic signatures associated with plasma oxytocin levels in children and adolescents with autism spectrum disorder [texte imprimé] / Stephen K. SIECINSKI, Auteur ; Stephanie N. GIAMBERARDINO, Auteur ; Marina SPANOS, Auteur ; Annalise C. HAUSER, Auteur ; Jason R. GIBSON, Auteur ; Tara CHANDRASEKHAR, Auteur ; Maria Del Pilar TRELLES, Auteur ; Carol M. ROCKHILL, Auteur ; Michelle L. PALUMBO, Auteur ; Allyson Witters CUNDIFF, Auteur ; Alicia MONTGOMERY, Auteur ; Paige SIPER, Auteur ; Mendy B. MINJAREZ, Auteur ; Lisa A. NOWINSKI, Auteur ; Sarah MARLER, Auteur ; Lydia C. KWEE, Auteur ; Lauren C. SHUFFREY, Auteur ; Cheryl ALDERMAN, Auteur ; Jordana WEISSMAN, Auteur ; Brooke ZAPPONE, Auteur ; Jennifer E. MULLETT, Auteur ; Hope CROSSON, Auteur ; Natalie HONG, Auteur ; Sheng LUO, Auteur ; Lilin SHE, Auteur ; Manjushri BHAPKAR, Auteur ; Russell DEAN, Auteur ; Abby SCHEER, Auteur ; Jacqueline L. JOHNSON, Auteur ; Bryan H. KING, Auteur ; Christopher J. MCDOUGLE, Auteur ; Kevin B. SANDERS, Auteur ; Soo-Jeong KIM, Auteur ; Alexander KOLEVZON, Auteur ; Jeremy VEENSTRA-VANDERWEELE, Auteur ; Elizabeth R. HAUSER, Auteur ; Linmarie SIKICH, Auteur ; Simon G. GREGORY, Auteur . - p.502-523. Langues : Anglais (eng) in Autism Research > 16-3 (March 2023) . - p.502-523 Index. décimale : PER Périodiques Résumé : Abstract Oxytocin (OT), the brain's most abundant neuropeptide, plays an important role in social salience and motivation. Clinical trials of the efficacy of OT in autism spectrum disorder (ASD) have reported mixed results due in part to ASD's complex etiology. We investigated whether genetic and epigenetic variation contribute to variable endogenous OT levels that modulate sensitivity to OT therapy. To carry out this analysis, we integrated genome-wide profiles of DNA-methylation, transcriptional activity, and genetic variation with plasma OT levels in 290 participants with ASD enrolled in a randomized controlled trial of OT. Our analysis identified genetic variants with novel association with plasma OT, several of which reside in known ASD risk genes. We also show subtle but statistically significant association of plasma OT levels with peripheral transcriptional activity and DNA-methylation profiles across several annotated gene sets. These findings broaden our understanding of the effects of the peripheral oxytocin system and provide novel genetic candidates for future studies to decode the complex etiology of ASD and its interaction with OT signaling and OT-based interventions. Lay Summary Oxytocin (OT) is an abundant chemical produced by neurons that plays an important role in social interaction and motivation. We investigated whether genetic and epigenetic factors contribute to variable OT levels in the blood. To this, we integrated genetic, gene expression, and non-DNA regulated (epigenetic) signatures with blood OT levels in 290 participants with autism enrolled in an OT clinical trial. We identified genetic association with plasma OT, several of which reside in known autism risk genes. We also show statistically significant association of plasma OT levels with gene expression and epigenetic across several gene pathways. These findings broaden our understanding of the factors that influence OT levels in the blood for future studies to decode the complex presentation of autism and its interaction with OT and OT-based treatment. En ligne : https://doi.org/10.1002/aur.2884 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=498

---

1 (1 - 3 / 3) Par page : 25 50 100 200